Plasma urocortin in acute myocardial infarction patients
- 19 August 2010
- journal article
- research article
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 40 (10) , 874-882
Abstract
Eur J Clin Invest 2010; 40 (10): 874–882 Abstract Background Despite its proposed cardioprotective effect, the role of plasma urocortin in acute myocardial infarction (AMI) remains unknown. We investigated plasma profile of urocortin in AMI patients and evaluated its long-term prognostic performance. Material and methods Sixty-six AMI patients and 21 healthy subjects were included in this study. Blood samples for urocortin were collected on days 0 (onset), 1, 3 and 5 and at 3 and 6 months. Primary endpoint was mortality within 1 year of follow-up. Secondary endpoint was combined death and nonfatal adverse cardiac events (i.e. myocardial reinfarction, urgent revascularization or hospitalization due to heart failure) within 1 year. Results During follow-up at 1 year, 38 (57·6%) patients were alive without cardiac events, nine (13·6%) had nonfatal cardiac events and 17 (25·8%) died. Plasma urocortin in AMI patients were increased on days 0, 1, 3 and 5 (P < 0·05 vs. control). The receiver-operating characteristic curve showed an area under curve (AUC) of day 0 urocortin to be 0·750 with 95% confidence interval (CI) of 0·619–0·881 (P = 0·004), whereas AUC of NT-proBNP was 0·857 (95% CI, 0·722–0·992; P = 0·003). Sensitivity values for predicting the mortality of urocortin NT-proBNP and a combined urocortin and NT-proBNP were 0·81 (95% CI, 0·54–0·95), 0·86 (95% CI, 0·42–0·99) and 1·0 (95% CI, 0·56–1·0), respectively. Conclusions Plasma urocortin level is elevated in AMI patients for 5 days from onset. High plasma urocortin within 24 h after the onset is associated with increased mortality. Combined urocortin and NT-proBNP enhance prognostic performance in AMI patients.Keywords
This publication has 30 references indexed in Scilit:
- A catalogue of reporting guidelines for health researchEuropean Journal of Clinical Investigation, 2009
- Universal definition of myocardial infarction: Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial InfarctionEuropean Heart Journal, 2007
- Improved early risk stratification and diagnosis of myocardial infarction, using a novel troponin I assay conceptEuropean Journal of Clinical Investigation, 2005
- Role and importance of biochemical markers in clinical cardiologyEuropean Heart Journal, 2004
- Plasma urocortin in human systolic heart failureClinical Science, 2004
- Role of Corticotropin-Releasing Factor Receptor Type 2β in Urocortin-Induced Vasodilation of Rat AortasJournal of Pharmacological Sciences, 2004
- Acute coronary syndrome: unstable angina and non-ST segment elevation myocardial infarctionBMJ, 2003
- Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE)**Further information about the project, along with a complete list of the study participants, can be found at www.outcomes.org/grace.The American Journal of Cardiology, 2002
- Urocortin Protects against Ischemic and Reperfusion Injury via a MAPK-dependent PathwayJournal of Biological Chemistry, 2000
- Ischaemic preconditioning and contractile function: Studies with normothermic and hypothermic global ischaemiaJournal of Molecular and Cellular Cardiology, 1992